Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
Together with existing cash, the proceeds will be used to fund the ongoing phase III trial of AP101, a potential treatment for Epidermolysis Bullosa
We’ll know how effective Lupuzor is when the top line data is shared with the market in the first quarter of next year
The 15 patients whose results are being analysed took part in a 2009/10 trial
Of significant note in the first-half was the commercial licence agreement with CRISPR Therapeutics
A tough and competitive market hit the firm's Generics business
If it is given the green light, the product would be the first and only new-class treatment to address the signs and symptoms of the ailment in adults in Europe
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
The label change relates to Cardioxane, which is given to protect the heart against certain chemotherapies called anthracyclines
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.